Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Outlook (2019-2023): Increasing Second- and Third-Line Therapies -

Research and Markets
Posted on: 04 Dec 18

The "Global Idiopathic Thrombocytopenic Purpura Therapeutics Market 2019-2023" report has been added to's offering.

The Global Idiopathic Thrombocytopenic Purpura Therapeutics Market is projected to grow at a CAGR of 5.41% during the period 2019-2023. One trend affecting this market is the development of combination therapy for ITP. The ITP market is coming up with many combination therapies for the treatment of the disease with many positive outcomes.

According to the report, one driver influencing this market is the increasing second- and third-line therapies. The global ITP therapeutics market is witnessing an increase in the inflow of second and third-line therapies to meet the unmet needs of ITP.

Further, the report states that one challenge affecting this market is the side effects of approved treatment. Many approved therapeutics cause serious side effects which is a key challenge in the global ITP therapeutics market.

Key Vendors

  • Amgen
  • Bristol-Myers Squibb
  • Eisai
  • Merck Sharp & Dohme
  • Novartis

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by Product

7. Customer Landscape

8. Geographic Landscape

9. Decision Framework

10. Drivers and Challenges

11. Market Trends

12. Vendor Landscape

13. Vendor Analysis

For more information about this report visit

View source version on

Business Wire

Last updated on: 04/12/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.